Angiotensin II Type 1 Receptor Blockers
"Angiotensin II Type 1 Receptor Blockers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.
| Descriptor ID |
D047228
|
| MeSH Number(s) |
D27.505.519.162.500
|
| Concept/Terms |
Angiotensin II Type 1 Receptor Blockers- Angiotensin II Type 1 Receptor Blockers
- Angiotensin II Type 1 Receptor Antagonists
- Type 1 Angiotensin Receptor Blockers
- Angiotensin 2 Type 1 Receptor Antagonists
- Type 1 Angiotensin Receptor Antagonists
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin II Type 1 Receptor Blockers".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin II Type 1 Receptor Blockers".
This graph shows the total number of publications written about "Angiotensin II Type 1 Receptor Blockers" by people in this website by year, and whether "Angiotensin II Type 1 Receptor Blockers" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiotensin II Type 1 Receptor Blockers" by people in Profiles.
-
Prevalence of angiotensin II type 1 receptor (AT1R)-activating autoantibodies in primary aldosteronism. J Am Soc Hypertens. 2015 Jan; 9(1):15-20.
-
Autoimmune mechanisms activating the angiotensin AT1 receptor in 'primary' aldosteronism. J Clin Endocrinol Metab. 2014 May; 99(5):1790-7.
-
Safety of symptom-limited cardiopulmonary exercise testing in patients with chronic heart failure due to severe left ventricular systolic dysfunction. Am Heart J. 2009 Oct; 158(4 Suppl):S72-7.
-
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis. Am J Med Sci. 2008 Oct; 336(4):330-5.
-
Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin. 2008 Sep; 24(9):2597-607.
-
Candesartan in heart failure. Clin Interv Aging. 2006; 1(4):357-66.
-
Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus. Pharmacotherapy. 2005 Nov; 25(11):1602-20.
-
Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm. 2004 Dec; 1(6):669-75.
-
Prevention of nitrate tolerance with angiotensin II receptor type 1 blocker in patients with stable angina: yet another failed strategy to prevent tolerance. Cardiovasc Drugs Ther. 2004 Sep; 18(5):339-42.